Newsletter - October 2015

How much is too much? Sometimes, too much business is a very good problem to have. What about information and data that is so vast that it becomes cumbersome for your business to function properly, and it feels like an anchor is pulling your business down? When dealing with larger datasets, organizations face difficulties in being able to…

Newsletter - September 2015

Diabetes is a widespread problem throughout the country. In fact, it's so prevalent that it's now commonplace. This is why various pharmaceuticals are quick to find a cure drug or, at the very least, a "band-aid" solution to this ever-growing problem. Which is why the Japanese pharmaceutical Takeda released Actos, a drug used to treat Type-2…

Newsletter - June 2015

Whenever a drug comes on the market to enhance the lives of its consumers, the drug, more probable than not, does anything but. One such example is Lipitor. Known by its technical moniker Atorvastatin, was marketed and used to lower cholesterol. However, not long after the FDA issued a warning that this statin has been linked to memory loss and…

Newsletter - May 2015

The drug Zofran (Ondansetron) was manufactured to help cancer patients to treat nausea that usually follows chemotherapy treatments. The FDA's approval of Zofran was limited to only this use. However, manufacturer GlaxoSmithKline took the liberty of marketing the drug to pregnant women to treat morning sickness. Unfortunately, not only did the…

Newsletter - April 2015

The drug Zofran (Ondansetron) was manufactured to help cancer patients to treat nausea that usually follows chemotherapy treatments. The FDA's approval of Zofran was limited to only this use. However, manufacturer GlaxoSmithKline took the liberty of marketing the drug to pregnant women to treat morning sickness. Unfortunately, not only did the…

Newsletter - January 2015

Boston Scientific Corp. (henceforth "Defendant"), a developer & manufacturer of medical devices, in November 2014, was ordered to pay four women over $26 million after a Miami federal court jury found that it was liable for marketing faulty Transvaginal mesh devices.